Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Autoimmune Connective Tissue Disease Cases
Description
The presentation discusses challenging cases of autoimmune connective tissue diseases, specifically focusing on two patient scenarios. The first case involves a 76-year-old woman with severe ulcerative skin lesions diagnosed with non-uremic calciphylaxis, a rare and serious condition marked by vascular calcification leading to tissue ischemia. The diagnosis involved careful evaluation of her medical history and biopsies, revealing risk factors associated with calciphylaxis, including long-term use of Prednisone and Warfarin. Treatment emphasized wound care, pain management, and sodium thiosulfate infusions, which led to marked improvement in her condition over four weeks.
The second case centers around a patient with dermatomyositis, recognizable by distinctive skin features requiring a robust treatment plan including sun protection, management of pruritus, and systemic therapies such as hydroxychloroquine, methotrexate, and IVIG. The presentation highlights the need for multidisciplinary approaches due to the high risk of drug reactions and varying responses to treatments. Notably, TNF inhibitors are advised against as they may exacerbate dermatomyositis symptoms. The session concluded with insights on the efficacy of various treatments derived from recent clinical findings and patient responses.
Conclusions
- Calciphylaxis is a rare and serious condition marked by vascular calcification leading to reduced blood flow and high mortality rates.
- The condition has multiple risk factors, including certain medications like glucocorticoids and warfarin, as well as underlying health issues such as kidney disease.
- Effective management of calciphylaxis involves comprehensive wound care, stopping contributing medications, and using treatments like sodium thiosulfate and vitamin K supplementation.
- In patients with dermatomyositis, cutaneous symptoms often require not only topical treatments but also systemic therapies involving antimalarials and immunosuppressants.
- Adverse skin reactions to medications like hydroxychloroquine are more common in dermatomyositis patients compared to those with cutaneous lupus.
- Intravenous immunoglobulin (IVIG) has shown effectiveness in treating refractory cases of dermatomyositis, providing significant improvements in skin symptoms and allowing for corticosteroid reduction.
- Current treatment approaches for dermatomyositis often require a multidisciplinary team due to the complexity of the disease and varied patient responses to medications.
- Cobos, Gabriela A., Alisa Femia, and Ruth Ann Vleugels. "Dermatomyositis: an update on diagnosis and treatment." American Journal of Clinical Dermatology 21.3 (2020): 339-353.
- Pelle, Michelle T., Jeffrey P. Callen. "Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus." Arch Dermatol. 2002;138:1231-1233.
- Pinard, Joanie, et al. "Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers." JAMA dermatology 155.4 (2019): 494-496.
- Femia, Alisa N et al. "Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center." Journal of the American Academy of Dermatology vol. 69,4 (2013): 654-7.
- Aggarwal, R., et al. "Trial of Intravenous Immune Globulin in Dermatomyositis." N Engl J Med 2022;387:1264-1278.
- Liu, Stephanie W., et al. "Dermatomyositis Induced by Anti-Tumor Necrosis Factor in a Patient With Juvenile Idiopathic Arthritis." JAMA Dermatology Published online August 28, 2013.
- Oddis, C.V. et al. "Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Placebo-Phase Trial." Arthritis Rheum. 2013 Feb;65(2):314-324.